Aura Biosciences (NASDAQ:AURA) Sees Large Volume Increase - Here's What Happened

Key Points

• Aura Biosciences shares traded unusually heavily, with about 718,007 shares changing hands—63% above the prior session—while the stock fell 0.9% to $7.607.
• Analyst views remain mixed: the stock carries a consensus “Hold” rating and a $17.50 target price, although recent reports included both downgrades to “Sell” and reduced price targets.
• The company reported a quarterly loss of $0.48 per share, missing expectations by $0.10. Aura is a clinical-stage biopharmaceutical company developing AU-011, a treatment candidate for choroidal melanoma.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 718,007 shares were traded during trading, an increase of 63% from the previous session's volume of 439,304 shares.The stock last traded at $7.6070 and had previously closed at $7.69.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AURA shares. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a research note on Tuesday, May 12th. Weiss Ratings upgraded Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 14th. Wall Street Zen cut Aura Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday. Finally, HC Wainwright decreased their target price on Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $17.50.

Aura Biosciences Stock Down 0.9%

The company has a market cap of $790.27 million, a P/E ratio of -4.35 and a beta of 0.40. The business has a fifty day moving average price of $7.02 and a 200-day moving average price of $6.75.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, research analysts expect that Aura Biosciences, Inc. will post -1.61 earnings per share for the current year.

Insiders Place Their Bets

In other Aura Biosciences news, insider Anthony S. Gibney sold 12,824 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the transaction, the insider owned 265,354 shares in the company, valued at $1,703,572.68. This trade represents a 4.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in Aura Biosciences in the 2nd quarter valued at about $29,000. Parallel Advisors LLC raised its position in shares of Aura Biosciences by 130.4% in the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock valued at $38,000 after buying an additional 3,206 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after buying an additional 2,104 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences in the fourth quarter valued at approximately $59,000. Finally, Water Island Capital LLC acquired a new stake in Aura Biosciences during the third quarter worth approximately $64,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source